Controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile6 entries
2025
Proposed dialysis-price antitrust class action
A benefits fund filed a proposed class action alleging that Fresenius and DaVita coordinated to restrict competition, allocate markets, and inflate outpatient dialysis prices. The claims remain allegations in pending litigation.
2024
FTC investigation into possible exclusionary conduct
The company disclosed an FTC investigation involving possible unfair or exclusionary conduct in the acquisition of medical-director services or the provision of dialysis services. The investigation concerned regulatory scrutiny rather than a final finding of liability.
2022
Fresenius Vascular Care False Claims Act allegations
The U.S. government alleged that Fresenius Vascular Care performed certain vascular procedures on dialysis patients without sufficient clinical indication and billed public and private healthcare programs. The case was a civil complaint and the allegations were not treated as a final adjudication.
2021
Fresenius Medical Care faces allegations over Malawi dialysis contracts
Issue disclosure
A Nyasa Times report said Fresenius Medical Care faced criticism in Malawi over an alleged effort to gain control of dialysis services and alleged corrupt practices related to government contracts. The allegations were reported, not established as findings in this article.
Source excerpt
South African-based firm, Fresenius Medical Care (FMC) has come under heavy fire from Malawians for their intended hostile takeover of the management of dialysis machines and units in the country.
More shocking is that this conduct has facilitated the gravity of corrupt practices within the government system where some officers are reported to have received bribes to disturb existing contracts and rope in Fresenius as an option to manage dialysis machines both at QECH and Kamuzu Central Hospital (KCH).
2019
Foreign Corrupt Practices Act settlement
U.S. authorities alleged that Fresenius entities used improper payments, third-party arrangements, and sham commissions to obtain or retain business in multiple countries. The company agreed to pay more than $231 million and accept independent compliance monitoring and other controls.
2000
Medicare testing and laboratory kickback case
National Medical Care and related subsidiaries pleaded guilty and entered civil settlements over allegations involving unnecessary laboratory testing, false claims, and illegal kickbacks for laboratory business. The combined criminal and civil resolution was approximately $486 million.